Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

• Published in: Hormone and metabolic research Vol. 54; no. 4; p. 238
• Main Authors: Yin, X, Takov, K, Straube, R, Voit-Bak, K, Graessler, J, Julius, U, Tselmin, S, Rodionov, Roman N, Barbir, M, Walls, M, Theofilatos, K, Mayr, M, Bornstein, S R
• Format: Journal Article
• Language: English
• Published: Germany 01.04.2022
• Subjects: Blood Component Removal - adverse effects; Blood Component Removal - methods; Cardiometabolic Risk Factors; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Cholesterol, LDL; Humans; Lipoprotein(a); Precision Medicine - adverse effects; Proteomics; Risk Factors; Treatment Outcome
• ISSN: 1439-4286
• DOI: 10.1055/a-1776-7943

Lipoprotein apheresis (LA) is currently the most powerful intervention possible to reach a maximal reduction of lipids in patients with familial hypercholesterolemia and lipoprotein(a) hyperlipidemia. Although LA is an invasive method, it has few side effects and the best results in preventing further major cardiovascular events. It has been suggested that the highly significant reduction of cardiovascular complications in patients with severe lipid disorders achieved by LA is mediated not only by the potent reduction of lipid levels but also by the removal of other proinflammatory and proatherogenic factors. Here we performed a comprehensive proteomic analysis of patients on LA treatment using intra-individually a set of differently sized apheresis filters with the INUSpheresis system. This study revealed that proteomic analysis correlates well with routine clinical chemistry in these patients. The method is eminently suited to discover new biomarkers and risk factors for cardiovascular disease in these patients. Different filters achieve reduction and removal of proatherogenic proteins in different quantities. This includes not only apolipoproteins, C-reactive protein, fibrinogen, and plasminogen but also proteins like complement factor B (CFAB), protein AMBP, afamin, and the low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) among others that have been described as atherosclerosis and metabolic vascular diseases promoting factors. We therefore conclude that future trials should be designed to develop an individualized therapy approach for patients on LA based on their metabolic and vascular risk profile. Furthermore, the power of such cascade filter treatment protocols may improve the prevention of cardiometabolic disease and its complications.